Geneva, June 20 -- International Clinical Trials Registry received information related to the study (ACTRN12625000610437) titled 'Real-World Evidence of Biosynthetic Semaglutide in Pakistan: A Multicenter Observational Study on Efficacy, and Quality of Life' on June 12.
Study Type: Observational
Study Design:
Purpose: Natural history
Duration: Longitudinal
Selection: Defined population
Timing: Prospective
Primary Sponsor: Ferozsons Laboratories
Condition:
Diabetes Type 2
Diabetes Type 2
Metabolic and Endocrine - Diabetes
Intervention:
Participants enrolled in this study are individuals who have been prescribed semaglutide as part of their routine clinical care for type 2 diabetes by their treating physicians, independent of study...